重新审视快速纠正低钠血症死亡率获益的新数据:似曾相识
该综述回顾了快速纠正严重慢性低钠血症与渗透性脱髓鞘综合征(ODS)争议的历史,指出支持快速纠正的旧研究存在转诊偏倚,新研究受混杂因素限制。作者认为快速纠正的风险包括不可逆神经损伤,临床应继续优先缓慢可控的钠纠正以保护高危患者。
要点
- 旧研究支持快速纠正存在转诊偏倚,新研究受混杂因素限制。
- 新旧研究均强调快速纠正后磁共振成像确诊的ODS罕见,但未在高危ODS患者中开展。
- 临床应继续优先缓慢可控的钠纠正,避免高危患者不可逆神经损伤。
核心结论
- 快速纠正低钠血症的风险包括不可逆神经损伤,临床应继续优先缓慢可控的钠纠正以保护高危患者。
主要发现
- 支持快速纠正的旧研究存在转诊偏倚,支持快速纠正的新研究受混杂因素限制,因合并症同时影响死亡率和低钠纠正速率。
- 新旧研究均强调快速纠正后磁共振成像确诊的ODS罕见,但均未在处于ODS风险的低钠血症患者中开展。
- 旧研究报道的低钠血症脑水肿死亡高估了真实发生率,新研究报道的死亡与缓慢钠纠正相关但未记录脑水肿作为常见死因。
临床怎么用
- 临床医生应继续优先采用缓慢、可控的钠纠正,以保护高危患者免受不可逆神经损伤。
局限性
- 需进一步研究以明确高危患者中ODS和脑水肿的真实发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies in the 1980s linking rapid correction of severe, chronic hyponatremia to the osmotic demyelination syndrome (ODS) led to a major controversy that eventually gave way to consensus guidelines. Efforts to limit correction to ≤8 mmol/L per day in patients at high risk of developing ODS became common practice. Recent studies have questioned these guidelines, suggesting that ODS is rare and that slow correction may increase mortality. In this review, we revisit the history of the controversy and find that these claims have persisted for 4 decades. Older studies supporting faster correction are flawed by referral bias while newer studies are limited by confounding as comorbidities influence rates of both mortality and hyponatremia correction. Although both old and new studies emphasize the rarity of magnetic resonance imaging-documented ODS after rapid correction, they were not conducted in hyponatremic patients who were at risk for ODS. Old studies reporting hyponatremic deaths due to cerebral edema overestimate its true incidence, and new studies reporting an association of mortality and slow rates of sodium correction do not document cerebral edema as a common contributor to death. Further research is required to better define the incidence of both ODS and cerebral edema in patients at risk for these complications. Until then, we conclude that the risks of rapid correction-including irreversible neurological damage-necessitate caution. Clinicians should continue to prioritize slow, controlled sodium correction to protect high-risk patients from harm.
引用
- Sterns RH, Rondon-Berrios H. Revisiting New Data on the Mortality Benefit of Rapid Correction of Hyponatremia: Déjà Vu All Over Again. Am J Kidney Dis. 2025. PMID: 41093163. doi:10.1053/j.ajkd.2025.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。